Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical and healthcare sectors, has introduced a cell based bioassay service to meet rising demand for potency assessments.
Cell based bioassays are the primary tool for determining the biological activity of molecules, making the potency tests a critical part of drug product and drug substance quality control, product release and stability testing. Biopharma companies need to generate this information to have confidence in their drugs and comply with…
In support of its continuing growth plans, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has appointed a new CMC regulatory affairs professional.
Claire Scruton joins Boyds as Senior Manager of CMC Regulatory Affairs and will be based at the organisation’s Cambridge office.
At Boyds, Claire will provide strategic regulatory CMC advice and operational support across a range of therapeutic areas and development stages for ATMPs, biologics and new chemical entities.
A CMC regulatory affairs professional, Claire…
Cell encapsulation for transport of cells and tissues at room temperature
Cambridge, UK and Newcastle, UK, 9th May 2019 / Sciad Newswire / Atelerix, creator of an innovative cell encapsulation technology, today announces it has closed a second round of funding of £700,000 to accelerate development of its cell transport products to market.
Atelerix’s products are used for the storage and transport of human cells and tissues at room temperature, removing the need for cryopreservation and the potential for cell degradation or damage. Atelerix sells its products and services to customers in the…
To support their ambitious growth plans, Dundee-based resourcing group Entrust Resource Solutions have acquired a second company, SCI Search and Selection, increasing their portfolio to three consultancies.
The specialist life sciences and healthcare resourcing group now comprise three like-minded consultancies located in key locations across the UK: Entrust People, Horton International UK and SCI Search and Selection. With the addition of a North West location, the group is closer to Manchester’s thriving life sciences industry, with world leading research and development assets, the largest…
Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin…
Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, ArestatTM to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner.
Under the collaboration, Arecor will leverage its ArestatTM technology to develop superior liquid formulations of its partner’s proprietary products. The partner will fund the development work and has the option to acquire the rights to the formulation and…
Study compares two in vitro liver methods to determine which one best predicts BDIs
Westbury, NY – May 2, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that its ADME-Tox team has co-authored a second peer-reviewed paper investigating the potential for clinically-relevant botanical-drug interactions (BDIs) with toxicology colleagues at The Procter & Gamble Company (P&G).1 The paper describes a research collaboration by BioIVT and P&G based on studies conducted in BioIVT’s laboratory in Durham, NC.
This new…
30 April 2019
Collaboration with BenevolentAI will use machine learning and artificial intelligence to discover potential new drugs for chronic kidney disease and idiopathic pulmonary fibrosis
AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
Scientists from the two organisations will work side-by-side to combine AstraZeneca’s genomics, chemistry and clinical data with…
NEW YORK, NY & LONDON, UK, April 30th 2019 (Newswire) -- Alpha MD, a London-based global leader in healthcare research analytics and consulting, and Liberate Ideas, Inc. the leading provider of digital patient education for physicians, announce today a partnership agreement in order to initiate integration of Liberate Health in the UK’s National Health Service(NHS).
Liberate Health is a fast-growing healthcare professional digital patient education platform that has been proven to increase the effectiveness of the education encounter and, more importantly, reduce the time required by the…